IC50: 2.27 and 4.78 μM against L1210 and K562 cell lines
Z-Ligustilide, isolated and purified from the essential oil of A. sinensis. Z-Ligustilide has been reported to facilitate blood circulation and attenuate inflammatory pain behavior.
In vitro: Previous results showed pretreatment with Z-Ligustilide (LIG) improved cell viability significantly. The apoptosis rate in glutamate-induced PC12 cells decreased in the presence of LIG. Western blot results indicated that LIG could decrease the release of Cyt C from mitochondria, up-regulate Bcl-2/Bax ratio and down-regulate Caspase-3 protein expression, resulting in protecting PC12 cells from apoptosis [1].
In vivo: In ovariectomized (OVX) osteopenic rats, the anti-inflammatory potential of LIG was determined by ELISA. LIG was found to be able to inhibit OVX-induced up-regulation of NF-κB activation and the production of TNF-α, iNOS, IL-1β, ICAM-1 and COX-2 significantly. In addition, LIG could suppress MDA and PMN infiltration. The significant anti-inflammatory effect of Z-Ligustilide in experimental OVX osteopenic rats clearly demonstrated that there might be an inflammatory component in the etiology of osteoporosis [2].
Clinical trial: N/A
References:
[1] Wu Q,Wang N,Wang Y,Wang GY,Piao XX. rotective effect of ligustilide against glutamate-induced apoptosis in PC12 cells. Yao Xue Xue Bao.2015 Feb;50(2):162-8.
[2] Ma Z,Bai L. The anti-inflammatory effect of Z-Ligustilide in experimental ovariectomized osteopenic rats. Inflammation.2012 Dec;35(6):1793-7.